Company Encyclopedia
View More
name
SIHUAN PHARM
00460.HK
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China and the United States. It operates through three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care, and others, as well as non- or minimally invasive medical aesthetics comprehensive solutions. It also provides drugs in the oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine, and industrial hemp therapeutic areas.
1.450 T
00460.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking21/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-1.83%D
    • Profit Margin-3.84%D
    • Gross Margin66.07%A
  • Growth ScoreC
    • Revenue YoY19.73%B
    • Net Profit YoY-113.66%E
    • Total Assets YoY-6.13%D
    • Net Assets YoY-1.11%D
  • Cash ScoreC
    • Cash Flow Margin-2601.37%E
    • OCF YoY19.73%B
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreC
    • Gearing Ratio53.48%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SIHUAN PHARM has signed a cooperation agreement with the American company AbaloneBio to jointly develop a new generation of innovative therapies for weight loss and muscle gain, further deepening its layout in the GPCR target field

    SIHUAN PHARM has signed a cooperation agreement with the American company AbaloneBio. Both parties will jointly develop a new generation of obesity treatment drugs, aiming to enhance energy expenditure and increase muscle mass by targeting metabolism-related G protein-coupled receptors (GPCRs). This collaboration will combine Abalone's antibody screening technology with SIHUAN PHARM's research and development resources in the field of metabolic diseases, aiming to optimize obesity treatment solutions, reduce research and development risks, and promote efficient project advancement

    Zhitong·
    HK
    00460
    -0.75%
    Zhitong·
    HK
    00460
    -0.75%

    SIHUAN PHARM repurchased 15 million shares at a total price of 21.76 million yuan

    SIHUAN PHARM announced that on October 17, it repurchased a total of 15 million shares from the market at an average price of 1.4505 yuan per share, with a total purchase price of approximately 21.76 million yuan

    AASTOCKS·
    HK
    00460
    -0.75%
    AASTOCKS·
    HK
    00460
    -0.75%

    On October 17th, SIHUAN PHARM spent HKD 21.7575 million to repurchase 15 million shares

    According to the Zhitong Finance APP, SIHUAN PHARM announced that it spent HKD 21.7575 million to repurchase 15 million shares on October 17, 2025

    Zhitong·
    HK
    00460
    -0.75%
    Zhitong·
    HK
    00460
    -0.75%

    Overview of Hong Kong Stock Buybacks: 37 Stocks Repurchased by Companies

    As of October 15, a total of 37 Hong Kong stocks have been repurchased by companies, among which Xiaomi Corporation-W, SIHUAN PHARM, and CLOUD FACTORY had the largest repurchase amounts, totaling HKD 98.9589 million, HKD 15.189 million, and HKD 8.0112 million, respectively. So far this year, 240 Hong Kong stocks have been repurchased, with 53 individual stocks having repurchase amounts exceeding HKD 100 million. Tencent Holdings Limited, HSBC HOLDINGS, and AIA Group had the largest repurchase amounts, totaling HKD 60.965 billion, HKD 29.414 billion, and HKD 17.693 billion, respectively

    Zhitong·
    HK
    00460
    -0.75%
    Zhitong·
    HK
    00460
    -0.75%

    On October 15th, SIHUAN PHARM spent HKD 15.189 million to repurchase 10 million shares

    According to the Zhitong Finance APP, SIHUAN PHARM announced that the company spent HKD 15.189 million to repurchase 10 million shares on October 15, 2025, with a repurchase price of HKD 1.5-1.54 per share

    Zhitong·
    HK
    00460
    -0.75%
    Zhitong·
    HK
    00460
    -0.75%
    © 2025 Longbridge｜Disclaimer